FDA panel backs Daiichi Sankyo's anti-stroke drug edoxaban
This article was originally published in Scrip
Executive Summary
The FDA's Cardiovascular and Renal Drugs Advisory Committee on 30 October voted 9-1 to recommend approval of Daiichi Sankyo's Factor Xa inhibitor edoxaban as a therapy to prevent stroke and systemic embolism events (SEE) in patients with nonvalvular atrial fibrillation (NVAF).